COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering

Résumé détaillé

TORONTO, ONTARIO, Nov. 13, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating…

TORONTO, ONTARIO, Nov. 13, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the third quarter ended September 30, 2026. All amounts in this press release are in U.S. dollars.

Peter Puccetti, CEO & Chairman of the Board of COSCIENS remarked “While we are very pleased that Ceapro Inc. (“Ceapro”) continues to show materially improved revenues and profitability versus a year ago, the highlight of this quarter is our acquisition of Nualtis Corp. (“Nualtis”). Nualtis provides us with greater scale as a public company and a new avenue of potentially significant future growth.

Dr. Michael Raven, CEO of Nualtis, added “The Nualtis team and I are excited about the opportunities ahead. More and more pharmaceutical companies see oral thin films as a smart and complementary way to develop their portfolios further. Our existing partnerships provide a strong foundation for growth, and we are working on a number of new OTF products with new and existing partners. Members of the Nualtis senior management team, including myself, have invested their own capital in the COSCIENS financing alongside COSCIENS’ management, Board members and outside investors.”

Mitch Regnier, Senior VP, Managing Director of Ceapro, added “We are proud of what we have accomplished so far this year. Sales and operational improvement efforts have put Ceapro back on a path to sustained growth and profitability. We are looking forward to building on that momentum and leveraging Ceapro’s core manufacturing capabilities, plant infrastructure and growing customer portfolio. Nualtis is a welcome addition to the COSCIENS team as we forge ahead to keep providing solid financial performance.”

Giuliano La Fratta, Chief Financial Officer of COSCIENS, commented “Over the last year, we have taken strong, definitive steps to improve COSCIENS’ cost structure such as: divesting the underperforming German businesses…

Début de l'article, extrait de Toronto Star. Pour lire la suite, ouvrez l'article chez le média.